1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
(
- Contribution to journal › Article
-
Mark
Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population-based Swedish chronic myeloid leukaemia registry
(
- Contribution to journal › Article
- 2017
-
Mark
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
(
- Contribution to journal › Article
- 2016
-
Mark
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
(
- Contribution to journal › Article
- 2015
-
Mark
Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation.
(
- Contribution to journal › Article
- 2009
-
Mark
Donor lymphocyte infusion as therapy for persistent pure red cell aplasia following major ABO-incompatible stem cell transplantation
2009) 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation In Bone Marrow Transplantation 43. p.373-373(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Permissive roles of hematopoietin and cytokine tyrosine kinase receptors in early T cell development
(
- Contribution to journal › Article
-
Mark
FLT3 ligand and not TSLP is the key regulator of IL-7-independent B-1 and B-2 B Lymphopoiesis.
(
- Contribution to journal › Article